Compare Stocks: ATYR, LUCD, PLX, and KRRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.54 -2.6%	$0.53	$0.40 ▼ $6.50	$52.97M	0.54	604,134 shs	256,892 shs
KRRO Korro Bio	$12.91 -2.6%	$12.78	$5.20 ▼ $55.89	$190.11M	3.04	91,309 shs	67,367 shs
LUCD Lucid Diagnostics	$0.99 +0.8%	$0.99	$0.86 ▼ $1.63	$201.50M	1.08	998,076 shs	423,293 shs
PLX Protalix BioTherapeutics	$2.54 -2.7%	$2.36	$1.52 ▼ $3.19	$204.65M	0.02	931,214 shs	490,228 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	+7.68%	+12.50%	-0.46%	-89.56%
KRRO Korro Bio	0.00%	-2.05%	+23.54%	-3.73%	-40.18%
LUCD Lucid Diagnostics	0.00%	+2.81%	+10.01%	-3.75%	-21.32%
PLX Protalix BioTherapeutics	0.00%	+6.72%	+11.89%	+20.38%	+58.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.54 -2.6%	$0.53	$0.40 ▼ $6.50	$52.97M	0.54	604,134 shs	256,892 shs
KRRO Korro Bio	$12.91 -2.6%	$12.78	$5.20 ▼ $55.89	$190.11M	3.04	91,309 shs	67,367 shs
LUCD Lucid Diagnostics	$0.99 +0.8%	$0.99	$0.86 ▼ $1.63	$201.50M	1.08	998,076 shs	423,293 shs
PLX Protalix BioTherapeutics	$2.54 -2.7%	$2.36	$1.52 ▼ $3.19	$204.65M	0.02	931,214 shs	490,228 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	+7.68%	+12.50%	-0.46%	-89.56%
KRRO Korro Bio	0.00%	-2.05%	+23.54%	-3.73%	-40.18%
LUCD Lucid Diagnostics	0.00%	+2.81%	+10.01%	-3.75%	-21.32%
PLX Protalix BioTherapeutics	0.00%	+6.72%	+11.89%	+20.38%	+58.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.25	Hold	N/A	N/A
KRRO Korro Bio	2.92	Moderate Buy	$16.71	29.47% Upside
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	322.38% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	372.44% Upside

Current Analyst Ratings Breakdown

Latest ATYR, LUCD, PLX, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/4/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $9.25

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	278.78	N/A	N/A	$0.50 per share	1.08
KRRO Korro Bio	$2.38M	79.81	N/A	N/A	$7.01 per share	1.84
LUCD Lucid Diagnostics	$4.71M	42.78	N/A	N/A	$0.05 per share	19.83
PLX Protalix BioTherapeutics	$80.62M	2.54	$0.14 per share	17.80	$0.47 per share	5.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.23	N/A	8.19	N/A	-21.03%	-30.89%	-11.74%	N/A

Latest ATYR, LUCD, PLX, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	$189.56 million
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.12	5.12
KRRO Korro Bio	N/A	9.55	9.55
LUCD Lucid Diagnostics	N/A	1.33	1.31
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
KRRO Korro Bio	13.18%
LUCD Lucid Diagnostics	74.01%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.75%
KRRO Korro Bio	4.80%
LUCD Lucid Diagnostics	6.90%
PLX Protalix BioTherapeutics	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	98.09 million	92.45 million	Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
LUCD Lucid Diagnostics	70	203.24 million	189.22 million	No Data
PLX Protalix BioTherapeutics	200	80.57 million	69.00 million	Optionable

ATYR, LUCD, PLX, and KRRO Headlines

Recent News About These Companies

Zacks Research Brokers Reduce Earnings Estimates for PLX

August 22, 2026 | americanbankingnews.com

Zacks Research Issues Pessimistic Outlook for PLX Earnings

August 20, 2026 | marketbeat.com

Protalix (PLX) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs

August 16, 2026 | kalkinemedia.comK

PLX: Elfabrio estimates up

August 13, 2026 | msn.com

Protalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approval

August 12, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

August 12, 2026 | finanznachrichten.de

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

August 12, 2026 | prnewswire.com

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

August 5, 2026 | prnewswire.com

Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary

May 15, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript

May 14, 2026 | insidermonkey.com

PLX: Chiesi Milestone Received

May 14, 2026 | finance.yahoo.com

Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call

May 14, 2026 | uk.finance.yahoo.com

Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...

May 14, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 13, 2026 | prnewswire.com

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

May 6, 2026 | prnewswire.com

Protalix: Elfabrio Struggles Against Oral Competition

April 15, 2026 | seekingalpha.com

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

March 24, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

March 18, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, LUCD, PLX, and KRRO Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.54 -0.01 (-2.63%)

As of 08/28/2026 04:00 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Korro Bio NASDAQ:KRRO

$12.91 -0.35 (-2.64%)

As of 08/28/2026 04:00 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Lucid Diagnostics NASDAQ:LUCD

$0.99 +0.01 (+0.75%)

As of 08/28/2026 04:00 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Protalix BioTherapeutics NYSE:PLX

$2.54 -0.07 (-2.68%)

As of 08/28/2026 04:00 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, LUCD, PLX, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, LUCD, PLX, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, LUCD, PLX, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, LUCD, PLX, and KRRO Company Descriptions

aTyr Pharma NASDAQ:ATYR

Korro Bio NASDAQ:KRRO

Lucid Diagnostics NASDAQ:LUCD

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, LUCD, PLX, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, LUCD, PLX, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, LUCD, PLX, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, LUCD, PLX, and KRRO Company Descriptions

aTyr Pharma NASDAQ:ATYR

Korro Bio NASDAQ:KRRO

Lucid Diagnostics NASDAQ:LUCD

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools